. Phosphorylation of S6K and S6RP precedes changes in skeletal muscle mass caused by Fst-288 and activation of PI3K/Akt. (A) The mass of TA muscles examined 3 d after injection of rAAV6:Fst-288 was not significantly different (ND) compared with control-injected muscles, despite increased expression of Fst-288 by Western blotting. (B) Increased phosphorylation of mTOR, S6K, and S6RP was evident in TA muscles 3 d after injection of rAAV6:Fst-288 (*, P < 0.01 vs. control), but there was no change in the phosphorylation of Akt or TSC2. (C) No difference was observed in the PI3K activity of muscles injected with rAAV6:Fst-288 compared with control-injected muscles. The assay was validated using heart lysates from IGF receptoroverexpressing mice (IGFR, which demonstrate higher levels of PI3K activity) and age-matched nontransgenic (NTG) animals. Neg, negative control with no antibody. Black lines indicate that intervening lanes have been spliced out. (D) The phosphorylation of ERK and RSK was not changed in response to Fst-288 at 3 d. Graphs show data from at least four independent experiments. Error bars indicate ± SEM. ). (F) Fst-288 expression does not alter ERK T202/204 phosphorylation in the skeletal muscles in wild-type mice. The TA muscles were harvested 4 wk after administration of rAAV6:Fst-288 to the hind limbs of 8-wk-old wild-type mice. Graphs show data from at least four independent experiments. Error bars indicate ± SEM.
